JP2017530982A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017530982A5 JP2017530982A5 JP2017518329A JP2017518329A JP2017530982A5 JP 2017530982 A5 JP2017530982 A5 JP 2017530982A5 JP 2017518329 A JP2017518329 A JP 2017518329A JP 2017518329 A JP2017518329 A JP 2017518329A JP 2017530982 A5 JP2017530982 A5 JP 2017530982A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- subject
- compound
- disorder
- sterol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
- 208000035475 disorder Diseases 0.000 claims description 25
- 229930182558 Sterol Natural products 0.000 claims description 22
- 150000003432 sterols Chemical class 0.000 claims description 22
- 235000003702 sterols Nutrition 0.000 claims description 22
- 239000002552 dosage form Substances 0.000 claims description 15
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 14
- IOWMKBFJCNLRTC-XWXSNNQWSA-N (24S)-24-hydroxycholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@H](O)C(C)C)[C@@]1(C)CC2 IOWMKBFJCNLRTC-XWXSNNQWSA-N 0.000 claims description 12
- IOWMKBFJCNLRTC-UHFFFAOYSA-N 24S-hydroxycholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(O)C(C)C)C1(C)CC2 IOWMKBFJCNLRTC-UHFFFAOYSA-N 0.000 claims description 12
- 235000012000 cholesterol Nutrition 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 230000009469 supplementation Effects 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 230000007812 deficiency Effects 0.000 claims description 7
- 238000011374 additional therapy Methods 0.000 claims description 6
- 239000007909 solid dosage form Substances 0.000 claims description 6
- 101100025412 Arabidopsis thaliana XI-A gene Proteins 0.000 claims description 5
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- 102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 claims description 4
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims description 4
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims description 4
- 208000019851 Opitz G/BBB syndrome Diseases 0.000 claims description 4
- 239000000902 placebo Substances 0.000 claims description 4
- 229940068196 placebo Drugs 0.000 claims description 4
- 230000036470 plasma concentration Effects 0.000 claims description 4
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 3
- 101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 claims description 3
- 229940123934 Reductase inhibitor Drugs 0.000 claims description 3
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 239000003613 bile acid Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 238000001415 gene therapy Methods 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000006194 liquid suspension Substances 0.000 claims description 3
- 238000013160 medical therapy Methods 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 229940075993 receptor modulator Drugs 0.000 claims description 3
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 3
- 229960002855 simvastatin Drugs 0.000 claims description 3
- 238000011477 surgical intervention Methods 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- IXRAQYMAEVFORF-CUFNGHRHSA-N (3S,8S,9S,10R,13S,14S,17S)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,16-diol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(O)[C@@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 IXRAQYMAEVFORF-CUFNGHRHSA-N 0.000 claims description 2
- INBGSXNNRGWLJU-ZHHJOTBYSA-N 25-hydroxycholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCCC(C)(C)O)C)[C@@]1(C)CC2 INBGSXNNRGWLJU-ZHHJOTBYSA-N 0.000 claims description 2
- INBGSXNNRGWLJU-UHFFFAOYSA-N 25epsilon-Hydroxycholesterin Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(CCCC(C)(C)O)C)C1(C)CC2 INBGSXNNRGWLJU-UHFFFAOYSA-N 0.000 claims description 2
- 208000025480 CHILD syndrome Diseases 0.000 claims description 2
- 208000027417 CK syndrome Diseases 0.000 claims description 2
- 208000019389 Greenberg dysplasia Diseases 0.000 claims description 2
- 208000028603 Interstitial lung disease specific to childhood Diseases 0.000 claims description 2
- 208000014060 Niemann-Pick disease Diseases 0.000 claims description 2
- 206010048215 Xanthomatosis Diseases 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 208000029560 autism spectrum disease Diseases 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 239000000155 melt Substances 0.000 claims description 2
- 230000002503 metabolic effect Effects 0.000 claims description 2
- 230000004060 metabolic process Effects 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 210000002435 tendon Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 24
- 206010072219 Mevalonic aciduria Diseases 0.000 claims 2
- 206010072221 mevalonate kinase deficiency Diseases 0.000 claims 2
- 230000001594 aberrant effect Effects 0.000 claims 1
- 208000017568 chondrodysplasia Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 22
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462060932P | 2014-10-07 | 2014-10-07 | |
| US62/060,932 | 2014-10-07 | ||
| PCT/US2015/054551 WO2016057713A1 (en) | 2014-10-07 | 2015-10-07 | Neuroactive compounds and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020149725A Division JP2020196759A (ja) | 2014-10-07 | 2020-09-07 | 神経刺激性化合物およびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017530982A JP2017530982A (ja) | 2017-10-19 |
| JP2017530982A5 true JP2017530982A5 (cg-RX-API-DMAC7.html) | 2018-11-15 |
Family
ID=55653736
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017518329A Withdrawn JP2017530982A (ja) | 2014-10-07 | 2015-10-07 | 神経刺激性化合物およびその使用方法 |
| JP2020149725A Withdrawn JP2020196759A (ja) | 2014-10-07 | 2020-09-07 | 神経刺激性化合物およびその使用方法 |
| JP2022000454A Pending JP2022033285A (ja) | 2014-10-07 | 2022-01-05 | 神経刺激性化合物およびその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020149725A Withdrawn JP2020196759A (ja) | 2014-10-07 | 2020-09-07 | 神経刺激性化合物およびその使用方法 |
| JP2022000454A Pending JP2022033285A (ja) | 2014-10-07 | 2022-01-05 | 神経刺激性化合物およびその使用方法 |
Country Status (17)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS64332B1 (sr) | 2011-09-08 | 2023-08-31 | Sage Therapeutics Inc | Neuroaktivni steroidi, kompozicije i njihova upotreba |
| RU2684103C2 (ru) | 2013-03-13 | 2019-04-04 | Сейдж Терапьютикс, Инк. | Нейроактивные стероиды и способы их применения |
| EP2970196B1 (en) | 2013-03-15 | 2020-11-25 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| EA032777B1 (ru) | 2013-12-24 | 2019-07-31 | Вирджиния Коммонвелт Юниверсити | Способ предотвращения или лечения почечной недостаточности |
| US10259840B2 (en) | 2014-06-18 | 2019-04-16 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| CA2991311C (en) * | 2015-07-06 | 2025-05-06 | Sage Therapeutics, Inc. | OXYSTEROLS AND THEIR METHODS OF USE |
| JP2018519328A (ja) | 2015-07-06 | 2018-07-19 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびそれらの使用の方法 |
| BR122021005552B1 (pt) | 2015-07-06 | 2024-01-02 | Sage Therapeutics, Inc | Compostos oxiesteróis, seus usos e composição farmacêutica |
| PT3436022T (pt) | 2016-04-01 | 2022-07-04 | Sage Therapeutics Inc | Oxisteróis e métodos de utilização dos mesmos |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| HUE055263T2 (hu) | 2016-07-07 | 2021-11-29 | Sage Therapeutics Inc | 11-Szubsztituált 24-hidroxiszterolok NMDA-hoz kapcsolódó állapotok kezelésére |
| CA3031224A1 (en) * | 2016-08-02 | 2018-02-08 | Shunlin Ren | Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide |
| ES2935057T3 (es) | 2016-09-30 | 2023-03-01 | Sage Therapeutics Inc | C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA |
| EP4616908A3 (en) | 2016-10-18 | 2025-11-26 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| JP7118957B2 (ja) * | 2016-10-18 | 2022-08-16 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびその使用方法 |
| EP3335730A1 (en) * | 2016-12-15 | 2018-06-20 | Fundació Institut de Recerca Biomédica de Bellvitge (IDIBELL) | Compounds for treating x-linked adrenoleukodystrophy |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US8604011B2 (en) * | 2004-09-27 | 2013-12-10 | The Regents Of The University Of California | Therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| GB0712494D0 (en) * | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
| MX2010004682A (es) * | 2007-11-06 | 2010-05-19 | Organon Nv | Metodo de supresion de hormonas en humanos. |
| KR20110016891A (ko) * | 2008-05-09 | 2011-02-18 | 에모리 유니버시티 | 신경정신 장애의 치료를 위한 ｎｍｄａ 수용체 길항물질 |
| WO2010065709A2 (en) * | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
| WO2010088414A2 (en) * | 2009-01-28 | 2010-08-05 | Emory University | Subunit selective nmda receptor potentiators for the treatment of neurological conditions |
| WO2011028794A2 (en) * | 2009-09-01 | 2011-03-10 | Lazarus Therapeutics, Inc. | Treatment of huntington's disease with cycloserine and an nmda receptor antagonist |
| KR101692275B1 (ko) * | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| US20120035156A1 (en) * | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
| RS64332B1 (sr) * | 2011-09-08 | 2023-08-31 | Sage Therapeutics Inc | Neuroaktivni steroidi, kompozicije i njihova upotreba |
| US20150119327A1 (en) * | 2012-04-25 | 2015-04-30 | The Regents Of The University Of California | Drug screening platform for rett syndrome |
| US9737522B2 (en) * | 2012-08-09 | 2017-08-22 | Emory University | NMDA receptor modulators and uses related thereto |
| PE20151437A1 (es) * | 2013-01-29 | 2015-10-10 | Naurex Inc | Moduladores de receptores nmda de espiro-lactama y sus usos |
| CN119269811A (zh) * | 2013-03-13 | 2025-01-07 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物、及其用途 |
| RU2684103C2 (ru) | 2013-03-13 | 2019-04-04 | Сейдж Терапьютикс, Инк. | Нейроактивные стероиды и способы их применения |
| US10259840B2 (en) * | 2014-06-18 | 2019-04-16 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| EP3166613A4 (en) * | 2014-07-09 | 2018-02-21 | Duke University | Compositions and methods for the repair of myelin |
| CA2991311C (en) * | 2015-07-06 | 2025-05-06 | Sage Therapeutics, Inc. | OXYSTEROLS AND THEIR METHODS OF USE |
-
2015
- 2015-10-07 PE PE2017000579A patent/PE20170907A1/es unknown
- 2015-10-07 MY MYPI2017000507A patent/MY202135A/en unknown
- 2015-10-07 KR KR1020177012221A patent/KR20170065637A/ko not_active Ceased
- 2015-10-07 IL IL292465A patent/IL292465B2/en unknown
- 2015-10-07 EP EP15849514.3A patent/EP3204011A4/en active Pending
- 2015-10-07 BR BR112017007053A patent/BR112017007053A2/pt not_active Application Discontinuation
- 2015-10-07 WO PCT/US2015/054551 patent/WO2016057713A1/en not_active Ceased
- 2015-10-07 AU AU2015330906A patent/AU2015330906A1/en not_active Abandoned
- 2015-10-07 MX MX2017004684A patent/MX388694B/es unknown
- 2015-10-07 JP JP2017518329A patent/JP2017530982A/ja not_active Withdrawn
- 2015-10-07 US US15/517,886 patent/US20170304321A1/en not_active Abandoned
- 2015-10-07 RU RU2017115849A patent/RU2764702C2/ru active
- 2015-10-07 CN CN201580063540.7A patent/CN107405352A/zh active Pending
- 2015-10-07 CA CA2963938A patent/CA2963938C/en active Active
- 2015-10-07 SG SG11201702799UA patent/SG11201702799UA/en unknown
- 2015-10-07 CN CN202011059273.5A patent/CN112121171A/zh active Pending
- 2015-10-07 SG SG10202011773UA patent/SG10202011773UA/en unknown
-
2017
- 2017-04-02 IL IL251505A patent/IL251505B/en unknown
- 2017-04-06 PH PH12017500639A patent/PH12017500639A1/en unknown
- 2017-04-07 MX MX2021011939A patent/MX2021011939A/es unknown
- 2017-04-10 ZA ZA2017/02545A patent/ZA201702545B/en unknown
-
2020
- 2020-09-07 JP JP2020149725A patent/JP2020196759A/ja not_active Withdrawn
-
2021
- 2021-02-04 AU AU2021200721A patent/AU2021200721B2/en active Active
-
2022
- 2022-01-05 JP JP2022000454A patent/JP2022033285A/ja active Pending
- 2022-09-19 US US17/947,844 patent/US20230218638A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017530982A5 (cg-RX-API-DMAC7.html) | ||
| RU2017115849A (ru) | Нейроактивные соединения и способы их применения | |
| US11160795B2 (en) | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus | |
| AU2012330885B2 (en) | Oral immediate release formulations for substituted quinazolinones | |
| CN104080339B (zh) | 高生物利用度的零价硫的制备和组合物及其用途 | |
| EP1715865B9 (en) | Hyperlipemia therapeutic agent comprising pitavastatins and eicosapentaenoic acid | |
| Singh et al. | Curcuma oil ameliorates hyperlipidaemia and associated deleterious effects in golden Syrian hamsters | |
| JPH10330251A (ja) | コレステロール低下剤 | |
| MXPA04012149A (es) | El uso de cianopirrolidinas sustituidas y prepraraciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas. | |
| JP5837919B2 (ja) | （ｅ）−４−カルボキシスチリル−４−クロロベンジルスルホンの改善された安定な水性製剤 | |
| US20250152535A1 (en) | Composition for preventing or improving hepatic dysfunction | |
| EP2744492A1 (en) | Combinations of corroles and statins | |
| NZ517276A (en) | Treatment of migraine by the administration of alpha-lipoic acid or derivatives thereof | |
| EP2926817A1 (en) | Stable pharmaceutical composition for treating osteoporosis | |
| JP2008063322A (ja) | ＨＭＧ−ＣｏＡリダクターゼ阻害剤、トコフェロール類及びＣｏＱ１０を含有する医薬組成物 | |
| TW200403053A (en) | A pharmaceutical composition for improving blood lipid or reducing blood homocysteine | |
| JP6227535B2 (ja) | 脂質異常症の予防又は治療薬 | |
| KR20190141773A (ko) | 변형 방출 니코틴아미드 | |
| CN106937952A (zh) | 依折麦布和辛伐他汀的制剂 | |
| JP5366386B2 (ja) | 神経細胞賦活及び神経伸長促進用組成物 | |
| CN110869019A (zh) | 用于治疗血脂异常的烟酰胺 | |
| AU2017305661A1 (en) | New use of N,N-bis-2-mercaptoethyl isophthalamide | |
| WO2025054311A1 (en) | Formulation containing taurursodiol and sodium phenylbutyrate | |
| EP4615462A1 (en) | Methods and compositions for treating wolfram syndrome | |
| WO2007116458A1 (ja) | 神経変性疾患治療薬 |